IPD’s Russian subscription brings transparency to this highly
complex and unique market, offering:

​

• Easy-to-use Russian brand,

       biosimilar, and generic drug

       launch tracking schedules

​

• Russian litigation tracking and

       in-the-courtroom coverage with 

       real-time updates

​

• Personalized consults with local Russian intellectual property analysts​

​

• Weekly updates including trending Russian drug topics, recent publications, and​

       loss-of-exclusivity information 

​​

• Comprehensive Russian clinical development tracking in every major disease class
   

• Complete drug information with locally reviewed Russian indications

​

• Russian API (DMF) information